Trial Profile
Low-dose Decitabine plus Crizotinib in EGFR-mutation-positive advanced non-small cell lung cancer patients :A open-label,single-arm phase II study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Jun 2016
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary) ; Decitabine (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 17 Jun 2016 New trial record